UNSPSC 51384203: Miroprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S00I5XG484, chemically known as 4-imidazo(1,2-a)pyridin-2-yl-alpha-methylbenzeneacetic acid but generally known as miroprofen, which bears US NIH Compound Identifier 68752. European Medicines Agency schedules Miroprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08994MIG.

UNSPSC 51384203 Miroprofen, a Commodity code, nominally describes a specific nonsteroidal anti-inflammatory drug product, but recent state and local procurement activity under this code does not align with that narrow scope. The three most recent opportunities solicited through this code classification involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which are miroprofen or closely related to it. The code shows a significant mismatch between its nominal definition and the work actually being tagged and bought under it in the state and local marketplace.

Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; and the Minnesota Multistate Cooperative Purchasing Alliance released RFP S1070000015802 in January 2026 to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026. The issuing bodies span county health systems, state health and human services departments, and cooperative purchasing alliances serving multiple states. The geographic spread includes Florida, Texas, Minnesota, and Oregon. The code's apparent miscategorization and the absence of any recent miroprofen-specific procurement signals warrant verification of the correct commodity code before pursuing opportunities under this classification.